We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

42 hedge funds and large institutions have $39.1M invested in Clearside Biomedical in 2020 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

112% more capital invested

Capital invested by funds: $18.4M → $39.1M (+$20.6M)

14% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 7

2% more funds holding

Funds holding: 41 → 42 (+1)

0.24% more ownership

Funds ownership: 1.72% → 1.97% (+0.24%)

0% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 10

Holders
42
Holders Change
+1
Holders Change %
+2.44%
% of All Funds
0.74%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
8
Increased
10
Reduced
10
Closed
7
Calls
$92K
Puts
–
Net Calls
+$92K
Net Calls Change
+$36K

Top Buyers

Rank Fund Capital Flow
1
CG
Carmignac Gestion
France
+$1.9M
2
ACP
Acuta Capital Partners
California
+$1.1M
3
Millennium Management
Millennium Management
New York
+$118K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$83.1K
5
SF
Synovus Financial
Georgia
+$48.5K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$120K
2
S
SignatureFD
Georgia
-$113K
3
Two Sigma Investments
Two Sigma Investments
New York
-$106K
4
Principal Financial Group
Principal Financial Group
Iowa
-$104K
5
Two Sigma Advisers
Two Sigma Advisers
New York
-$92.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$58K – – –
AG
27
Aperio Group
California
$52K – – –
IAN
28
Integrated Advisors Network
Texas
$43K – – –
Stifel Financial
29
Stifel Financial
Missouri
$38K +$78 +3 +0.3%
Cambridge Investment Research Advisors
30
Cambridge Investment Research Advisors
Iowa
$27K +$17.3K +667 New
UBS Group
31
UBS Group
Switzerland
$24K -$17.2K -663 -52%
PNC Financial Services Group
32
PNC Financial Services Group
Pennsylvania
$15K – – –
TRCT
33
Tower Research Capital (TRC)
New York
$13K -$13.4K -516 -62%
Morgan Stanley
34
Morgan Stanley
New York
$12K +$7.39K +285 New
Group One Trading
35
Group One Trading
Illinois
$12K +$7.81K +301 New
JP Morgan Chase
36
JP Morgan Chase
New York
$7K -$6.9K -266 -61%
Osaic Holdings
37
Osaic Holdings
Arizona
$7K – – –
PA
38
Parallel Advisors
California
$5K – – –
Wells Fargo
39
Wells Fargo
California
$1K -$73.1K -2,817 -99%
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$22 – – –
Principal Financial Group
41
Principal Financial Group
Iowa
– -$104K -4,521 Closed
Squarepoint
42
Squarepoint
New York
– -$51K -2,189 Closed
WS
43
Wedbush Securities
California
– -$32K -1,393 Closed
JIC
44
Johnson Investment Counsel
Ohio
– -$31K -1,333 Closed
DADC
45
D.A. Davidson & Co
Montana
– -$19K -833 Closed
PAM
46
Panagora Asset Management
Massachusetts
– -$4K -166 Closed
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
– -$2.65K -102 -99%
Simplex Trading
48
Simplex Trading
Illinois
– +$7.96K +307 New
1
2

CLSD Hedge Fund Activity: Q4 2020 in Review

42 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2020, worth a combined $39.1M — up 112% from $18.4M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CLSD positions and 7 closed out — a net gain of 1 holder — while 10 added to existing stakes and 10 trimmed.

The largest buyer was Carmignac Gestion, adding an estimated $1.9M. The largest seller was Renaissance Technologies, cutting an estimated $120K.

  • 42 institutional investors held Clearside Biomedical (CLSD) as of Q4 2020, up from 41 in Q3 2020.
  • Funds reported $39.1M of Clearside Biomedical stock for Q4 2020, up 112% quarter-over-quarter.
  • 8 funds opened new Clearside Biomedical positions in Q4 2020 and 7 closed out, a net change of +1 holder.
  • The largest Clearside Biomedical buyer in Q4 2020 was Carmignac Gestion, an estimated $1.9M added.
  • The largest Clearside Biomedical seller in Q4 2020 was Renaissance Technologies, an estimated $120K sold.

Based on aggregated 13F filings for Q4 2020.